Use of Oncotype DX in Women with Node-Positive Breast Cancer
Women with early stage breast cancer frequently receive adjuvant chemotherapy to prevent recurrence; however, not all patients benefit. Recently, gene expression marker panels, such as Oncotype DX, that may better predict risk of breast cancer recurrence have become commercially available and are be...
Main Authors: | Ishibe, Naoko, Schully, Sheri, Freedman, Andrew, Ramsey, Scott David |
---|---|
Format: | Online |
Language: | English |
Published: |
Public Library of Science
2011
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145540/ |
Similar Items
-
Oncotype Dx Results in Multiple Primary Breast Cancers
by: Toole, Michael J., et al.
Published: (2014) -
The analytical validation of the Oncotype DX Recurrence Score assay
by: Baehner, Frederick L
Published: (2016) -
Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
by: Malo, Teri L., et al.
Published: (2012) -
Use of Epidermal Growth Factor Receptor Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer to Determine Erlotinib Use as First-Line Therapy
by: Ishibe, Naoko, et al.
Published: (2011) -
Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
by: Varga, Zsuzsanna, et al.
Published: (2013)